Home » Grant » Page 2

Weight Loss Coaching Via Phone Aids Breast Cancer Patients, Study Finds

Published: November 8, 2024 | Last Updated: November 8, 2024


Boston, MA – A year-long study has demonstrated that a telephone-based weight loss intervention can lead to ample and clinically meaningful weight reduction in women diagnosed with Stage II or III breast cancer who are also overweight or obese. The findings, released this week, suggest a readily accessible approach to improving the health and well-being of this vulnerable patient population.

Researchers discovered that the intervention was universally effective across diverse demographic and racial backgrounds, though the degree of success varied. Postmenopausal women and those identifying as non-Black or non-Hispanic experienced greater benefits from the program.

The Challenge of Weight and Breast Cancer

The link between obesity and adverse outcomes in breast cancer patients is well established. Excess weight is associated with increased risk of cancer recurrence, higher mortality rates, the development of other health problems, and a diminished quality of life. Prior research exploring weight loss strategies in this group has been limited by small sample sizes, a focus on predominantly White populations, and the logistical challenges of in-person programs.

How the Study Worked

The study, involving 3,180 women with Stage II/III hormone receptor-negative breast cancer and a Body Mass Index (BMI) of 27 or higher, randomly assigned participants to one of two groups. One group (1,591 women) received a two-year telephone-based weight loss program combined with standard health education materials. The control group (1,589 women) received only the health education materials.

The weight loss program emphasized caloric restriction – ranging from 1,200 to 1,800 calories daily based on individual weight – and increased physical activity, starting at 150 minutes per week and escalating to 225 minutes.

Key Findings and Results

After one year, women in the intervention group experienced an average weight loss of 4.3 kg (approximately 9.5 pounds), representing 4.7% of their initial body weight. In contrast, the control group gained an average of 0.9 kg (about 2 pounds), or 1.0% of their baseline weight. The difference between the groups was statistically significant,with a mean difference of 5.3 kg (11.7 pounds) (P < .001).

Nearly half (46.5%) of the women in the intervention group achieved a clinically significant weight loss of at least 5% of their starting weight, compared to just 14.3% in the control group (P < .001). Furthermore, 22.5% of the intervention group lost 10% or more of their initial weight, while only 5.0% of the control group reached that milestone (P < .001).

Subgroup Analysis Reveals Nuances

Analysis of specific subgroups showed that postmenopausal women benefited more from the program, with a mean weight loss difference of 6.37%, compared to 4.82% for premenopausal women.Similarly, women of non-Black and non-Hispanic backgrounds experienced greater weight loss (mean difference of 6.11%) than Black and Hispanic participants (mean differences of 3.74% and 4.14% respectively).

The study also noted a positive correlation between the number of coaching calls completed and weight loss, with participants completing an average of 26 out of 30 scheduled calls. Premenopausal and Black/Hispanic women tended to participate in fewer calls than their counterparts.

Group Mean Weight Change (kg) Percentage of Participants Achieving ≥5% Weight Loss
Intervention Group -4.3 46.5%
Control Group 0.9 14.3%

Did You Know? Obesity is linked to increased inflammation, which can promote cancer growth and spread. Maintaining a healthy weight can support the immune system to fight cancer cells.

The Growing Importance of Lifestyle Interventions in Cancer Care

The findings underscore a growing recognition of the vital role that lifestyle interventions – such as diet and exercise – play in complete cancer care. Historically, cancer treatment has focused primarily on medical interventions like surgery, chemotherapy, and radiation. However, research increasingly demonstrates that addressing modifiable lifestyle factors can significantly impact treatment outcomes, quality of life, and long-term survival.

The accessibility of telephone-based coaching makes this approach particularly promising for reaching a wider range of patients, especially those facing geographic or logistical barriers to in-person programs. As of october 2023, the U.S. Centers for Disease Control and Prevention (CDC) estimates over 40% of adults in the United States have obesity, highlighting the need for scalable and effective weight management solutions.

Pro tip: Consider seeking support from a registered dietitian or certified personal trainer to develop a personalized weight management plan tailored to your specific needs and health status.

Frequently Asked Questions About Weight Loss and Breast Cancer

  1. What is a clinically significant weight loss? A clinically significant weight loss is generally considered to be at least 5% of initial body weight, as this amount is often associated with improvements in health markers.
  2. Is phone-based coaching as effective as in-person weight loss programs? This study demonstrates that telephone-based coaching can be effective, offering a convenient and accessible alternative to in-person programs.
  3. Why were some subgroups more successful than others in the study? Factors like menopausal status and racial/ethnic background may influence program engagement and metabolic responses to weight loss interventions.
  4. What is the ideal calorie intake for this weight loss program? Calorie intake varied from 1,200 to 1,800 calories per day, individualized based on a participant’s baseline weight.
  5. How does weight loss impact breast cancer recurrence? Maintaining a healthy weight is linked to a reduced risk of cancer recurrence, though further research is needed to determine the optimal degree of weight loss for maximum benefit.
  6. What are the limitations of this study? Over 20% of the participants had missing one-year weight data.
  7. Is this study enough to change the standard of care for breast cancer patients? While promising, the authors call for further research with greater weight loss to definitively assess the impact on prognosis.

Do you think telephone-based coaching could be a viable option for cancer patients in your community? Share your thoughts in the comments below!


What specific resources, such as coaching or educational materials, are available through the mobile program?

Mobile Program Enhances Weight Loss Among Breast Cancer Patients

The Link Between breast Cancer, Weight, and Mobile Health

Maintaining a healthy weight is crucial for overall well-being, but it takes on added significance for individuals undergoing breast cancer treatment. Weight gain or loss can substantially impact treatment efficacy, side effect management, and quality of life. Increasingly, mobile health (mHealth) interventions – utilizing smartphones and apps – are proving to be effective tools in supporting breast cancer patients achieve and sustain weight loss goals. This article explores how thes programs work, their benefits, and what patients can expect. We’ll cover topics like breast cancer weight management, mHealth for cancer survivors, and digital health interventions.

Why Weight Management Matters During and After Breast Cancer Treatment

Several factors contribute to weight fluctuations during breast cancer treatment:

Treatment Side Effects: Chemotherapy, radiation, and hormonal therapies can cause nausea, fatigue, and changes in metabolism, leading to weight changes.

Reduced Physical Activity: Treatment-related fatigue frequently enough limits physical activity, contributing to weight gain.

Emotional Eating: the stress and anxiety associated with a cancer diagnosis can lead to emotional eating and unhealthy food choices.

Metabolic Changes: Cancer and it’s treatment can alter metabolic rates and body composition.

excess weight, even moderate weight gain, is linked to:

Increased risk of breast cancer recurrence.

Worsened treatment side effects.

Increased risk of other chronic diseases like heart disease and diabetes.

Reduced quality of life.

Conversely, unintended weight loss can indicate malnutrition and weaken the immune system, hindering recovery.Cancer-related weight loss is a serious concern.

How Mobile Programs Facilitate Weight Loss

Mobile programs typically incorporate several key features to promote weight loss:

personalized Goal Setting: Apps allow patients to set realistic and achievable weight loss goals based on their individual needs and treatment plans.

Diet Tracking: Food diaries and calorie counters help patients monitor their dietary intake and make informed food choices. Nutrition for breast cancer patients is a key component.

Activity Tracking: Integration with wearable devices or smartphone sensors tracks physical activity levels, encouraging patients to stay active.

Behavioral support: Many apps offer motivational messages, reminders, and educational content on healthy eating and exercise. Behavioral weight loss programs are often very effective.

Remote Coaching: Some programs provide access to registered dietitians or health coaches for personalized guidance and support via text or video conferencing.

Progress Monitoring: Visual charts and graphs track progress, providing positive reinforcement and identifying areas for enhancement.

Evidence-Based Results: What the research Shows

Several studies demonstrate the effectiveness of mobile programs in supporting weight loss among breast cancer patients. A recent meta-analysis published in the Journal of Clinical Oncology showed that mHealth interventions led to statistically significant weight loss compared to usual care. Specifically, participants using mobile apps lost an average of 2-3 pounds more than those who did not.

Moreover, research indicates that these programs are especially beneficial for:

Patients undergoing chemotherapy.

Survivors experiencing weight gain after treatment.

Individuals with limited access to traditional weight management resources.

Choosing the Right Mobile Program: Key Considerations

With a plethora of apps available, selecting the right program can be overwhelming. Consider these factors:

Evidence-Based Approach: Look for programs developed by healthcare professionals and based on established weight loss principles.

Personalization: Choose an app that allows for customization based on your individual needs, treatment plan, and preferences.

User-Friendliness: The app should be easy to navigate and understand.

Integration with Wearables: compatibility with your existing fitness tracker can streamline data tracking.

Privacy and Security: Ensure the app protects your personal health information.

Cost: compare pricing models and features to find a program that fits your budget. Affordable weight loss solutions are important for accessibility.

Benefits Beyond Weight Loss: Improved Quality of Life

The benefits of mobile programs extend beyond just the numbers on the scale. Patients often report:

Increased energy levels.

Improved mood and reduced stress.

Enhanced self-efficacy and confidence.

Better adherence to treatment plans.

Improved overall quality of life.

These programs empower patients to take an active role in their health and well-being, fostering a sense of control during a challenging time. Breast cancer recovery is frequently enough enhanced by proactive health management.

Practical Tips for Success with a Mobile Weight Loss Program

Set Realistic goals: Start small and gradually increase your goals as you progress.

Be Consistent: Make tracking your food and activity a daily habit.

Seek Support: Share your goals with friends, family, or a support group.

Don’t Be Afraid to Ask for help: Utilize the resources available through your mobile program, such as coaching or educational materials.

Celebrate Your Successes: Acknowledge and reward yourself for achieving milestones.

Integrate with Your Healthcare Team: Discuss your weight loss goals and program with your oncologist and other healthcare providers.

0 comments
0 FacebookTwitterPinterestEmail

Beyond the Birthday: Rethinking Oxaliplatin Use in Colorectal Cancer Treatment

For decades, age has been a crude but common yardstick in cancer treatment decisions. But a new analysis of over 8,500 patients is challenging that approach, particularly when it comes to oxaliplatin chemotherapy for colorectal cancer (CRC). The study reveals a stark difference: while oxaliplatin significantly improves survival in stage III CRC patients up to age 70, that benefit vanishes for those over 70. Even more striking, the drug shows no survival advantage for patients with stage II disease, regardless of age. This isn’t simply about adding years to life; it’s about ensuring the right patients receive treatments that truly work, and avoiding unnecessary side effects for those who won’t benefit.

The Shifting Landscape of Oxaliplatin Therapy

Oxaliplatin has long been a cornerstone of adjuvant chemotherapy – treatment given after surgery – for stage II and III CRC. However, its effectiveness in older adults has been a subject of debate, with previous studies yielding conflicting results. Some research suggested continued benefit even in those over 70, while others found no improvement. This latest research, published in JAMA Network Open, aimed to resolve this uncertainty by meticulously analyzing a large, population-based cohort from Korea.

Stage Matters: A Clear Divide

The Korean study’s findings are particularly clear. For patients with stage II CRC, oxaliplatin offered no discernible survival benefit across all age groups. Adjusted hazard ratios ranged from 0.71 to 1.09, indicating no statistically significant impact. However, the picture changed dramatically for stage III patients. Those 70 and under experienced a substantial improvement in 5-year overall survival (84.8% vs. 78.1% with fluoropyrimidine alone), corresponding to an adjusted hazard ratio of 0.59. But beyond age 70, the benefit disappeared, with survival rates mirroring those of patients receiving fluoropyrimidine only (71% vs. 68%).

Beyond Chronological Age: The Rise of ‘Biological Age’

These results aren’t advocating for a rigid age cutoff. Researchers and oncologists are increasingly recognizing that biological age – a composite measure of frailty, organ function, and overall health – is a more accurate predictor of chemotherapy outcomes than simply counting years. As Nadine Jackson, MD, MPH, of Harvard Medical School, emphasizes, “We need to be cautious that we don’t interpret the results as an age threshold.” Factors like comorbidities, cognitive function, and social support all play a crucial role in a patient’s ability to tolerate and benefit from aggressive treatment.

The Discontinuation Dilemma: Tolerability and Treatment Success

The study also highlighted a significant trend: discontinuation rates of oxaliplatin-based regimens increased steadily with age, peaking at 37.4% for patients over 70 compared to 23.9% for younger patients. Importantly, discontinuation was directly linked to worse overall survival. This suggests that older patients may experience greater difficulty tolerating the drug’s side effects, potentially diminishing its effectiveness. As an editorial accompanying the study pointed out, clinicians need to be more cautious when recommending oxaliplatin to those over 70, and carefully assess individual patient factors.

Future Trends: Personalized Oncology and Geriatric Assessment

This research underscores a broader shift in oncology towards personalized treatment strategies. The “one-size-fits-all” approach is giving way to a more nuanced understanding of individual patient characteristics. Expect to see increased emphasis on comprehensive geriatric assessments – detailed evaluations of physical and cognitive function, nutritional status, and psychosocial factors – to guide treatment decisions. Furthermore, research into biomarkers that predict oxaliplatin sensitivity and toxicity will be crucial. The National Cancer Institute provides detailed information on oxaliplatin and its use in cancer treatment.

The Role of Technology and Data Analytics

Advanced data analytics and machine learning are poised to play a significant role in refining these personalized approaches. By analyzing vast datasets of patient information, researchers can identify patterns and predict which patients are most likely to benefit from oxaliplatin, and which are at higher risk of experiencing debilitating side effects. This will allow for more informed and individualized treatment plans, maximizing benefit and minimizing harm.

The future of colorectal cancer treatment isn’t about abandoning oxaliplatin, but about using it more intelligently. It’s about moving beyond chronological age and embracing a holistic assessment of each patient’s unique circumstances. What are your thoughts on the evolving role of age and biological factors in cancer treatment? Share your perspective in the comments below!

0 comments
0 FacebookTwitterPinterestEmail

TOPLINE:

Patients with inflammatory bowel disease (IBD) had a significantly higher risk for developing interstitial lung disease (ILD) compared with the general population and siblings who do not have the condition.

METHODOLOGY:

  • Although pulmonary complications of IBD have been recognized for over a decade, they remain largely unstudied.
  • Researchers conducted a population-based cohort study in Sweden between 1969 and 2019 to assess the long-term risk for ILD in 85,705 patients diagnosed with IBD (median age, 41 years; 48% women).
  • They matched these patients to 412,677 control individuals from the general population (median age, 41 years; 48% women) and to 101,278 IBD-free siblings of the patients (median age, 39 years; 49% women).
  • The primary outcome was incident ILD, a broad group of lung diseases characterized by inflammation and fibrosis that often lead to respiratory failure.

TAKEAWAY:

  • During a median follow-up of 14 years, ILD was diagnosed in 0.51% of patients with IBD vs 0.30% of control individuals, corresponding to incidence rates of 34 and 20 per 100,000 person-years, respectively.
  • Patients with IBD had a 48% higher risk of developing ILD than the matched control individuals and an 81% higher risk than their siblings.
  • Subgroup analyses found similar adjusted hazard ratios (aHRs) for ILD across IBD subtypes (ulcerative colitis1.59; Crohn’s disease, 1.34; and IBD unclassified, 1.24) vs the general population.
  • The highest risk for ILD diagnosis was observed within the first 2 years after the diagnosis of IBD (aHR, 2.14); however, the risk remained elevated even after 10 years (aHR, 1.24).
  • A subgroup analysis showed that the relative risk for ILD was notably higher in women with IBD and in adults aged 40 years or older with IBD.

IN PRACTICE:

“The findings from this study highlight the need for further data on lung function and capacity in patients with IBD, with a special focus on patients with additional risk factors for ILD. These data also support clinicians maintaining a higher index of suspicion for ILD in their IBD patients with pulmonary symptoms,” the authors wrote.

SOURCE:

This study, led by Bharati Kochar, MD, MS, Division of Gastroenterology, Massachusetts General Hospital, Boston, was published online on August 4 in The American Journal of Gastroenterology.

LIMITATIONS:

Researchers were unable to confirm diagnoses of ILD with chest imaging and pulmonary function testing. The patient cohort lacked granular disease-level detail on some risk factors for the development of ILD, including laboratory measures and endoscopic data. Limited data on medication use in the cohort prevented the consideration of potential relationships between treatments for IBD and the development of ILD.

DISCLOSURES:

The study was funded by a National Institute on Aging grant to Kochar and support from Karolinska Institutet for another author. Three authors reported receiving consulting fees, advisory fees, or financial support or having other ties with pharmaceutical companies.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

0 comments
0 FacebookTwitterPinterestEmail

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.